Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pki-166. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 10/20 | 0.50 |
| ▸ | LDHA | P00338 | 7/20 | 0.44 |
| ▸ | LDHB | P07195 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pki-166 SCHEMBL173524 | 1.00 | EGFR (0.50) | EGFRLDHALDHBLMNASMN1; SMN2 | |
| Pki-166 SCHEMBL19873163 | 0.87 | EGFR (0.74) | EGFRKDR | |
| SCHEMBL20474796 | 0.86 | EGFR (0.41) | EGFRLDHALDHB | |
| Aee-788 SCHEMBL29143573 | 0.79 | KDR (0.58) | EGFRSMN1; SMN2KDR | |
| SCHEMBL23827644 | 0.75 | NUDT1 (0.44) | EGFRKDR | |
| SCHEMBL4148819 | 0.68 | LDHA (0.47) | EGFRLDHALDHB | |
| Pki-166 SCHEMBL209560 | 0.67 | EGFR (1.00) | EGFRKDR | |
| Pki-166 SCHEMBL30883827 | 0.67 | EGFR (1.00) | EGFRKDR | |
| Pki-166 SCHEMBL185822 | 0.67 | EGFR (1.00) | EGFRKDR | |
| Pki-166 SCHEMBL29352405 | 0.67 | EGFR (1.00) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207805-B1 | NLRR-1 ANTAGONISTS AND USES THEREOF | GENENTECH INC (US) | 2014-07-09 | — | — | EP | claimed |
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748453-A2 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137798-A1 | MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102349-A1 | ANTI-INTERLEUKIN-23 RECEPTOR VHH ANTIBODIES AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2026-05-07 | — | — | US | disclosed |
| EP-4155415-B1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | GENENTECH INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | GENENTECH INC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2007134210-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | GENENTECH, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| CN-101023100-A | HER2 antibody composition | GENENTECH INC | 2007-08-22 | — | — | CN | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066522-A1 | Tumor inhibition by modulating sprouty expression or activity | MICHIGAN STATE UNIVERSITY (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060275305-A1 | HERCEPTIN adjuvant therapy | GENENTECH, INC. | 2006-12-07 | — | — | US | disclosed |
| US-20060263349-A1 | Pretreatment of a biological sample from an autoimmune disease subject | GENENTECH, INC. | 2006-11-23 | — | — | US | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| US-20060018899-A1 | HER2 antibody composition | GENENTECH, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | BCL6, BCL6B, MALT1 | EGFR 120/4885LDHA 2731/4885LDHB 1389/4885 |
| US-20260137798-A1 | MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | CD79B, BCL6, CD209 | EGFR 1328/4885LDHA 587/4885LDHB 137/4885 |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3C2B, PIK3C2A, PIK3CA | EGFR 46/4885LDHA 2184/4885LDHB 1720/4885 |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | APOL1, PDCD1LG2, PRSS1 | EGFR 264/4885LDHA 2102/4885LDHB 1138/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | EGFR 1/4885LDHA 2489/4885LDHB 2728/4885 |
| US-20060275305-A1 | HERCEPTIN adjuvant therapy | ERBB2, BRCA1, EGFR | EGFR 3/4885LDHA 1992/4885LDHB 1212/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | EGFR 2/4885LDHA 2268/4885LDHB 1751/4885 |
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | FUCA2, LNPEP, EEA1 | EGFR 746/4885LDHA 405/4885LDHB 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.